Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc.
7 Hills Pharma, LLC
Regeneron Pharmaceuticals
Alpha Tau Medical LTD.
Iovance Biotherapeutics, Inc.
University of Thessaly
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Fred Hutchinson Cancer Center
Massachusetts Eye and Ear Infirmary
Obsidian Therapeutics, Inc.
Institute of Health Information and Statistics of the Czech Republic
Rhode Island Hospital
Filamon LTD
Mayo Clinic
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
National Institutes of Health Clinical Center (CC)
Ankyra Therapeutics, Inc
Replimune Inc.
Washington University School of Medicine
University of Florida
Institute of Oncology Ljubljana
Institute of Oncology Ljubljana
Dana-Farber Cancer Institute
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Peter MacCallum Cancer Centre, Australia
University of Nebraska
Linkoeping University
Iovance Biotherapeutics, Inc.
Elephas
Massachusetts General Hospital
Elephas
OncoNano Medicine, Inc.
University of Modena and Reggio Emilia
University of Wisconsin, Madison
Rutgers, The State University of New Jersey
Emory University
University of Oklahoma
Universitaire Ziekenhuizen KU Leuven
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
Cancer Research UK
Massive Bio, Inc.
Dana-Farber Cancer Institute